| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TACC3 |
| Uniprot No | Q9Y6A5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-100 aa |
| 活性数据 | MSLQVLNDKNVSNEKNTENCDFLFSPPEVTGRSSVLRVSQKENVPPKNLAKAMKVTFQTPLRDPQTHRILSPSMASKLEAPFTQDDTLGLENSHPVWTQK |
| 分子量 | 36.74kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"TACC3 is essential for the regulation of spindle microtubule dynamics during mitosis" by Gergely, F. et al.**
- 该研究通过重组TACC3蛋白揭示了其与微管动态调控的直接关联，证实TACC3通过结合微管稳定纺锤体结构，为细胞分裂中的染色体精确分离提供机制支持。
2. **"Structural and functional analysis of the human TACC3 in breast cancer" by Lin, J. et al.**
- 利用重组TACC3蛋白进行体外实验，发现其在乳腺癌细胞中过表达会促进微管聚合和细胞增殖，揭示TACC3作为潜在癌症治疗靶点的作用。
3. **"The TACC domain modulates the microtubule-binding activity of TACC3" by Schmidt, S. et al.**
- 通过重组蛋白截断体实验，鉴定TACC3羧基端结构域(TACC domain)是其结合微管的关键区域，并证明磷酸化修饰可调控其活性，影响有丝分裂进程。
4. **"TACC3 promotes glioma cell proliferation through stabilization of Aurora-A kinase" by Molina, H. et al.**
- 重组TACC3蛋白与Aurora-A激酶的互作实验表明，二者协同维持胶质瘤细胞的有丝分裂活性，为TACC3在肿瘤发生中的分子机制提供了新视角。
**Background of Recombinant Human TACC3 Protein**
The Transforming Acidic Coiled-Coil-containing protein 3 (TACC3) is a member of the TACC family, which plays critical roles in mitotic spindle assembly, chromosomal alignment, and cell cycle regulation, particularly during the G2/M phase transition. TACC3 interacts with Aurora kinases and microtubules, stabilizing spindle fibers and ensuring faithful chromosome segregation. Its dysregulation is linked to genomic instability and is associated with cancers, including breast, lung, and ovarian malignancies.
Structurally, TACC3 contains a conserved C-terminal coiled-coil domain essential for microtubule binding and a unique N-terminal region involved in protein interactions. The human *TACC3* gene, located at 4p16.3. is amplified in some tumors, driving overexpression. Recombinant TACC3 protein is produced using heterologous expression systems (e.g., *E. coli*, insect cells) to study its biochemical functions, structural dynamics, and interactions. Tagged versions (e.g., His-, GST-tagged) simplify purification and enable *in vitro* assays exploring its role in mitosis, microtubule stabilization, or drug screening.
Research on recombinant TACC3 has advanced understanding of its oncogenic potential and therapeutic targeting. Inhibitors disrupting TACC3-microtubule interactions are under investigation as anticancer agents. However, challenges remain in resolving its conformational flexibility and post-translational modifications. Overall, recombinant TACC3 serves as a vital tool for deciphering mitotic mechanisms and developing targeted therapies.
(Word count: 240)
×
